Clearance of Alzheimer’s amyloid-β1-40 peptide from brain by LDL receptor–related protein-1 at the blood-brain barrier
Open accessThe DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index; 16 of the 62 sources its claims cite were checked for support.
Abstract
Elimination of amyloid-ss peptide (Ass) from the brain is poorly understood. After intracerebral microinjections in young mice, (125)I-Ass(1-40) was rapidly removed from the brain (t(1/2) </= 25 minutes), mainly by vascular transport across the blood-brain barrier (BBB). The efflux transport system for Ass(1-40) at the BBB was half saturated at 15.3 nM, and the maximal transport capacity was reached between 70 nM and 100 nM. Ass(1-40) clearance was substantially inhibited by the receptor-associated protein, and by antibodies against LDL receptor-related protein-1 (LRP-1) and alpha(2)-macroglobulin (alpha(2)M). As compared to adult wild-type mice, clearance was significantly reduced in young and old apolipoprotein E (apoE) knockout mice, and in old wild-type mice. There was no evidence that Ass was metabolized in brain interstitial fluid and degraded to smaller peptide fragments and amino acids before its transport across the BBB into the circulation. LRP-1, although abundant in brain microvessels in young mice, was downregulated in older animals, and this downregulation correlated with regional Ass accumulation in brains of Alzheimer's disease (AD) patients. We conclude that the BBB removes Ass from the brain largely via age-dependent, LRP-1-mediated transport that is influenced by alpha(2)M and/or apoE, and may be impaired in AD.
Overview
CoChat Summary
TL;DR
In mice, intracerebrally injected ¹²⁵I-Aβ1-40 is rapidly cleared from brain, mainly by LRP-1-mediated transport across the blood-brain barrier, with clearance influenced by α2M and apoE. LRP-1 downregulation in older mice and in Alzheimer’s disease brain regions correlates with Aβ accumulation, suggesting impaired vascular clearance may contribute to AD.
Key findings
- After intracerebral microinjection in young mice, total brain efflux half-time for ¹²⁵I-Aβ1-40 was 25.5 ± 2.0 minutes versus 239.0 ± 12.5 minutes for [¹⁴C]inulin (9.4-fold difference); BBB transport accounted for 73.8% of efflux, ISF bulk flow 10.7%, and 15.6% remained retained at 60 nM.
- Aβ1-40 clearance was concentration-dependent, half-saturated at 15.3 nM, and maximal between 70 nM and 100 nM. Anti-LRP-1 antibody inhibited clearance by about 55% (58% at 12 nM and 53% at 60 nM), RAP inhibited by 30–44%, and anti-α2M inhibited by 25%; anti-LRP-2 and anti-RAGE had no effect.
- There was no evidence of significant Aβ1-40 degradation in brain ISF before transport: injected peptide was >97% intact, 93.7% remained intact at 60 minutes, and only 4.2–9.9% of brain ¹²⁵I radioactivity was non-TCA-precipitable within 270 minutes; plasma degradation increased from 37.6% to 58.3% between 15 and 120 minutes.
- Clearance was reduced in apoE knockout and older mice: 30% reduction in young apoE KO mice, about 55% and 40% reductions in 9-month-old wild-type and apoE KO mice at 12 nM, and 46% reduction in 9-month-old apoE KO mice at 60 nM. LRP-1-positive brain vessels dropped from 94% in 2-month-old mice to 52% in 9-month-old mice, and reduced LRP-1 staining in AD frontal cortex correlated with regional Aβ accumulation.
Methods
- Male C57BL/6 wild-type and apoE knockout mice at 8–10 weeks and 9–10 months received intracerebral microinjections into the right caudate nucleus of ¹²⁵I-Aβ1-40 (0.05–120 nM) plus [¹⁴C]inulin; clearance was measured from 10 to 300 minutes, with dose and inhibitor studies at 30 minutes.
- Radioactivity was analyzed by TCA precipitation, HPLC, and SDS-PAGE; compartmental modeling separated BBB transport, ISF bulk flow, and brain retention. Inhibitors included anti-LRP-1 R777, RAP, anti-α2M, anti-LRP-2, anti-RAGE, fucoidin, and BCH.
- Immunocytochemistry was performed in mouse brain and human frontal cortex/cerebellum from 3 AD patients and 3 age-matched controls (postmortem 4–7 hours), using antibodies against LRP-1, α2M, Aβ1-40/1-42, and CD105.
Limitations
- The paper does not state limitations explicitly. Evident from the text: the mouse clearance model uses synthetic ¹²⁵I-Aβ1-40 and intracerebral injection, which may not fully reflect endogenous Aβ production and clearance.
- Evident: human data are correlational and based on only 3 AD patients and 3 controls; LRP-1 involvement is inferred from antibody/RAP inhibition and immunostaining rather than direct transport assays.
- Evident: the identity of an alternative low-concentration BBB transport mechanism remains unknown, α2M staining cannot distinguish circulating from microvessel-associated α2M, and age comparisons are limited to young versus 9-month-old mice.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
12 Valid · 0 Not valid · 21 Not checked · 114 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Previous studies from our laboratory and others have demonstrated a major role of the BBB in determining the concentrations of A b in the CNS by regulating transport of circulating A b (33, 39, 49-51, 62-66).”
What the sources say
- Partly supportedcites [33] Mackic, 1998, J Clin Invest sourceExperimental — accuracy not yet measured
The Discussion reports transport of circulating Aβ across a human BBB cell model and says that this transport would tend to increase Aβ accumulation in the brain. It does not demonstrate that the BBB has a major role in determining CNS Aβ concentrations in vivo; the paper describes that broader implication as likely. Page numbers are unavailable in our copy. (LLM, conf=0.84)
- Partly supportedcites [39] Zlokovic, 1996, Proc Natl Acad Sci USA sourceExperimental — accuracy not yet measured
The paper’s opening summary (page not specified in our copy) reports transport of Aβ–apolipoprotein J complexes across the blood–brain barrier into brain tissue in a guinea pig model. It does not establish that this transport has a major role in determining overall CNS Aβ concentrations, as the citing sentence claims. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [49] Maness, 1994, Life Sci source
- Not checked — no full text of the sourcecites [50] Poduslo, 1997, Neurobiol Dis source
- Not checked — no full text of the sourcecites [51] Martel, 1997, J Neurochem source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Binding/uptake studies in mouse embryonic fibroblasts (wild type and deficient in LRP-1), confirmed that free A b is not a ligand for LRP-1 (37, 45).”
What the sources say
- Partly supportedcites [37] Narita, 1997, J Neurochem sourceExperimental — accuracy not yet measured
The Abstract and Discussion report that free Aβ degradation was not inhibited by RAP and describe it as LRP-independent. But Table 1 tested free Aβ in human U87 glioblastoma cells; the mouse embryonic fibroblast comparison tested Aβ complexed with α2-macroglobulin, not free Aβ. Thus the paper supports the LRP-independent uptake conclusion, but not the claim that the fibroblast studies confirmed it. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [45] Kounnas, 1995, Cell source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Because normal aging is associated with A b accumulation in the brain (1)”
What the sources say
- Supportedcites [1] Wisniewski, 1997, Neurobiol Dis source
The section on the amyloid cascade hypothesis says that extensive Aβ-containing preamyloid deposits can be found in aged individuals with no reported clinical symptoms. This supports the claim that brain Aβ accumulation is associated with normal aging; the paper does not say it occurs in every older person. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This makes re-entry of radiolabeled A b into the brain very unlikely, because the blood-to-brain transport of A b normally operates down the concentration gradient (39, 62-65).”
What the sources say
- Partly supportedcites [39] Zlokovic, 1996, Proc Natl Acad Sci USA sourceExperimental — accuracy not yet measured
The paper’s study summary (page not identified in our copy) reports transport of Aβ–apolipoprotein J complexes from blood into brain parenchyma. It does not say that this transport normally follows a concentration gradient or that re-entry of radiolabeled Aβ is unlikely. (LLM, conf=0.78)
- Not checked — no full text of the sourcecites [62] Zlokovic, 1993, Biochem Biophys Res Commun source
- Not checked — no full text of the sourcecites [63] Ghilardi, 1996, Neuroreport source
- Not checked — no full text of the sourcecites [64] Shayo, 1997, Life Sci source
- Partly supportedcites [65] Martel, 1996, Neurosci Lett sourceExperimental — accuracy not yet measured
The discussion passage in our copy (labeled Abstract; page unavailable) says that a lower soluble Aβ42 concentration on the brain side of the BBB would provide a thermodynamic impetus for transport from capillaries into brain. It does not establish that blood-to-brain transport normally operates down a concentration gradient or that re-entry of radiolabeled Aβ is very unlikely; the study also observed uptake of radiolabeled Aβ in perfused guinea-pig brains. (LLM, conf=0.80)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“RAP, a chaperone protein that facilitates proper folding and subsequent trafficking of LRP-1 and LRP-2 (69), also inhibited A b clearance.”
What the sources say
- Partly supportedcites [69] Bu, 1996, J Biol Chem sourceExperimental — accuracy not yet measured
The citation is attached to the description of RAP as a folding and trafficking chaperone, not to the citing authors’ statement that RAP inhibited Aβ clearance. The paper’s Discussion supports that role for LRP, but does not establish it for the separate receptor LRP-2; its use of “LRP2” denotes a domain of LRP. (LLM, conf=0.89)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
92 more claims
Create a free account to see all 147 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 30
- Probably not a substantial claim. 25
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“For example, transport studies using radiolabeled and unlabeled Alzheimer's A 𝛃 peptide have shown that under physiological conditions, the perivascular ISF flow contributes to 15-20% of A 𝛃 clearance from the mouse brain (58, 535, 659), whereas 8085% is removed by transvascular BBB transport.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [535]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LRP1 binds Alzheimer's A 𝛃 toxin and mediates its brain-to-blood clearance (58, 137, 535, 561).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [535]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several groups have reported that trans-BBB efflux of Aβ into peripheral blood circulation is one of the main pathways of physiological clearance with ApoE, ApoJ, and ApoA1 as chaperones27,31,32.”
From Brain-targeted drug delivery by manipulating protein corona functions (2019) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LRP1 and LRP2 are expressed in brain endothelium and colocalize mainly on the abluminal side of the BBB in humans and rodents (137, 404, 535, 607, 682).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [535]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“whereas 8085% is removed by transvascular BBB transport.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [535]
Experimental — accuracy not yet measured
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Results · p. 5
“The HPLC analysis of brain radioactivity confirmed the TCA results by indicating that 93.7% of the peptide remains intact in brain ISF at 60 minutes (Figure 3b, right).”
§ Figure 3 · p. 6
“( b ) Left panel shows HPLC elution profile of brain tissue 60 minutes after intracerebral microinjection of 125 I-A b 1-40 (60 nM). Separation was performed for 30 mg of brain tissue on a reverse-phase HPLC column, using a 30-minute linear gradient of 25-83% acetonitrile in 0.1% TFA, pH 2. 125 I-A b 1-40 eluted at 52%, corresponding to the elution time of A b 1-40 standard. Right panel shows SDS-PAGE analysis”
Citations
Cites
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431 · cited 10×
“No anti-Aβ1-40–positive or Aβ1-42–positive staining was seen in either AD or control tissues.”
BackgroundInfluentialCorrelative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210 · cited 2×
“Because normal aging is associated with Aβ accumulation in the brain (1), and there is a significant, timedependent, and progressive accumulation of the peptide with age in transgenic APP animals (54, 55), we postulated that Aβ clearance mechanisms might be impaired in older animals, and are also possibly impaired in…”
BackgroundRAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., et al. (1996) · Nature · doi:10.1038/382685a0 · Cited by 2,012 · cited 9×
“In contrast, anti–LRP-2 Ab (Figure 4b) and anti-RAGE Ab (Figure 4c) did not affect Aβ clearance.”
BackgroundInfluentialIsolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
HYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542
Production of the Alzheimer Amyloid β Protein by Normal Proteolytic Processing
Shoji, M., Golde, T. E., Ghiso, J., Cheung, T. T., Estus, S., Shaffer, L. M., Cai, X.-D., McKay, D. M., Tintner, R., Frangione, B., et al. (1992) · Science · doi:10.1126/science.1439760 · Cited by 1,447 · cited 1×
“β-amyloid (1-42) is a major component of cere-”
BackgroundSelf-citationHolcomb, L., Gordon, M. N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., Saad, I., Mueller, R., Morgan, D., et al. (1998) · Nature Medicine · doi:10.1038/nm0198-097 · Cited by 1,386 · cited 1×
“Because normal aging is associated with Aβ accumulation in the brain (1), and there is a significant, timedependent, and progressive accumulation of the peptide with age in transgenic APP animals (54, 55), we postulated that Aβ clearance mechanisms might be impaired in older animals, and are also possibly impaired in…”
BackgroundAlzheimer's Disease--Genotypes, Phenotype, and Treatments
Selkoe, D. J. (1997) · Science · doi:10.1126/science.275.5300.630 · Cited by 875 · cited 1×
“β-amyloid (1-42) is a major component of cere-”
BackgroundIwata, N., Tsubuki, S., Takaki, Y., Watanabe, K., Sekiguchi, M., Hosoki, E., Kawashima-Morishima, M., Lee, H.-J., Hama, E., Sekine-Aizawa, Y., et al. (2000) · Nature Medicine · doi:10.1038/72237 · Cited by 867 · cited 8×
“However, the physiological relevance of the proposed degradation mechanism for Aβ1-42 (28) remains unclear, because the peptide was studied at extremely high concentrations (∼ 240 μM) that are not found even in brains with severe β-amyloidosis (30).”
BackgroundMethodResultInfluentialThe cell biology of β-amyloid precursor protein and presenilin in Alzheimer's disease
Selkoe, D. (1998) · Trends in Cell Biology · doi:10.1016/s0962-8924(98)01363-4 · Cited by 862 · cited 1×
“β-amyloid (1-42) is a major component of cere-”
Background
Research works printed but not linked: 4
- Suzuki, 1994, Am J Pathol, 145, 452
- Urmoneit, 1997, Lab Invest, 77, 157
- Yamada, 1991, Am J Physiol, 261, H1197
- Kounnas, 1994, In Vivo, 8, 343
Cited by
Items 1,101–1,200 of 1,448
Das, R., Nachbar, R. B., Edelstein‐Keshet, L., Saltzman, J. S., Wiener, M. C., Bagchi, A., Bailey, J. A., Coombs, D., Simon, A. J., Hargreaves, R. J., et al. (2010) · Bulletin of Mathematical Biology · doi:10.1007/s11538-010-9540-5 · Cited by 9
“This assumption is informed by evidence for receptor-mediated Aβ transport across the BBB, with LRP-1 and RAGE as likely receptors for Aβ transport (Deane et al. 2003; Shibata et al. 2000 ; Z lokovic2004).”
BackgroundBlood-borne factors inhibit Alzheimer's β-amyloid fibril formation in vitro
Ono, K., Noguchi‐Shinohara, M., Samuraki, M., Matsumoto, Y., Yanase, D., Iwasa, K., Naiki, H., & Yamada, M. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.05.019 · Cited by 9
Lipid metabolism and Alzheimer's disease: pathways and possibilities
Saxena, U. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220902738720 · Cited by 9
“It is of great interest to note that LRP, one of the key receptor’s involved in day-to-day lipoprotein metabolism has also been shown to be a major receptor which binds A β peptides and may be involved in their clearance [58-62] .”
BackgroundSivapackiam, J., Gammon, S. T., Harpstrite, S. E., & Sharma, V. (2009) · Methods in molecular biology · doi:10.1007/978-1-60761-416-6_8 · Cited by 10
Osborn, K. E., Alverio, J., Dumitrescu, L. C., Pechman, K. R., Initiative, A. D. N., Gifford, K. A., Hohman, T. J., Blennow, K., Zetterberg, H., & Jefferson, A. L. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190077 · Cited by 10
“blood-brain barrier [19] and through interstitial fluid bulk flow between perivascular”
Liang, R., Ou, S., Han, Y., Xu, J., & Zhou, S. (2019) · Experimental Gerontology · doi:10.1016/j.exger.2019.110737 · Cited by 9
Shi, X., Ren, S., Zhang, B., Guo, S., He, W., Yuan, C., Yang, X., Ig-lzevbekhai, K., Sun, T., Wang, Q., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-90982-1 · Cited by 9
Amyloid beta emerges from below the neck to disable the brain
Kauwe, G., & Tracy, T. E. (2021) · PLoS Biology · doi:10.1371/journal.pbio.3001388 · Cited by 10
“The soluble Aβ detected in blood could be peptides that are cleared into the blood from the brain [3], but Aβ can also originate from cells in the periphery.”
BackgroundBrain cortical cholesterol metabolism is highly affected by human APP overexpression in mice
Löffler, T., Schweinzer, C., Flunkert, S., Sántha, M., Windisch, M., Steyrer, E., & Hutter‐Paier, B. (2016) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2016.03.004 · Cited by 9
Elfakhri, K. H., Duong, Q.-V., Langley, C., Depaula, A., Mousa, Y. M., Lebeouf, T., Cain, C. M., & Kaddoumi, A. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.03.028 · Cited by 9
“Our findings showed Phen, Tph and BrG significantly upregulated the levels of both P-gp and LRP1, which could explain, at least in part, the increased transport of 125I-Aβ40.”
BackgroundInfluentialMolecular Determinants of Alzheimer’s Disease Aβ Peptide Neurotoxicity
Cappai, R., & Barnham, K. J. (2007) · Future Neurology · doi:10.2217/14796708.2.4.397 · Cited by 9
Masters, C. L., & Beyreuther, K. T. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.4.317 · Cited by 9
“For example, the variable propensity of these 3 distinct amyloid proteins to diffuse through the extracellular space from their sites of neuronal origin, and then precipitate around the outer surfaces of small arterioles and capillaries, sometimes provoking the drusige Entartung of Scholz, raises many interesting ques…”
BackgroundImmunization treatment approaches in Alzheimer’s and prion diseases
Wısnıewskı, T., & Sigurdsson, E. M. (2002) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-002-0065-7 · Cited by 11
Soria-Tobar, L., Román-Valero, L., Sebastián‐Serrano, Á., Aivar, P., Alvarez‐Castelao, B., & Díaz-Hernández, M. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01600-x · Cited by 8
“Lipoproteins may increase the clearance of Aβ from the brain [11], by promoting the amyloid transport from the brain to peripheral blood [44].”
BackgroundNeuropathological links between T2DM and LOAD: systematic review and meta-analysis
Lemche, E., Hortobágyi, T., Kiecker, C. M., & Turkheimer, F. (2025) · Physiological Reviews · doi:10.1152/physrev.00040.2024 · Cited by 11
Shanmugam, N. K. N., Zamudio, F., Kumar, D. K. V., Barrett, K. A., VanDoren, R., Chen, M., Barr, O. M., Watson, S., Lin, C., Eimer, W. A., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70292 · Cited by 11
DKK3-LRP1 complex and a chemical inhibitor regulate Aβ clearance in models of Alzheimer’s disease
Yang, R., Wang, L., Li, Y., Zhu, J., Wang, J., Schlessinger, D., & Sima, J. (2025) · Science Advances · doi:10.1126/sciadv.adz2099 · Cited by 8
“LRP1 also facilitates the transcytosis of A β across the BBB, with subsequent clearance via peripheral organs such as the liver, spleen, and kidney ( 10 , 11 ).”
Peng, H., Bukuroshi, P., Durk, M. R., Grootendorst, P. V., Yan, X., Pan, S. R., de Lannoy, I. A. M., & Pang, K. S. (2021) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2297 · Cited by 9
“…(BBB) is mediated primarily by P‐glycoprotein (P‐gp) (Cirrito et al., 2005; Lam et al., 2001) that is responsible for more than 60% of Aβ removal (Qosa et al., 2012), and to a lesser extent by the low‐density lipoprotein receptor‐related protein 1 (LRP1) (Deane et al., 2004; Shibata et al., 2000).”
BackgroundModelling cerebrovascular pathology and the spread of amyloid beta in Alzheimer’s disease
Ahern, A., Thompson, T., Oliveri, H., Lorthois, S., & Goriely, A. (2025) · Proceedings of the Royal Society A Mathematical Physical and Engineering Sciences · doi:10.1098/rspa.2024.0548 · Cited by 9
Peng, H., Noh, K., Pan, S. R., Saldivia, V., Serson, S., Toscan, A., de Lannoy, I. A. M., & Pang, K. S. (2020) · Drug Metabolism and Disposition · doi:10.1124/dmd.120.090886 · Cited by 9
Role of Human Serum Albumin in the Prevention and Treatment of Alzheimer’s Disease
Shevelyova, M. P., Deryusheva, E. I., Леонидовна, Н. Е., Валериевич, М. А., & Андреевна, Л. Е. (2024) · Biology Bulletin Reviews · doi:10.1134/s2079086424010109 · Cited by 9
“At the same time, the studies conducted in animal models demonstrated that the half-life of A β between the cerebrospinal fluid and plasma is about 30 min (Ghersi-Egea et al., 1996; Poduslo et al., 1999; Shibata et al., 2000).”
Low, K. J. Y., Phillips, M., & Pervushin, K. V. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00862 · Cited by 10
Du, S.-S., Sun, X., Cen, J., Shi, J.-X., An, M., & Zhao, W. (2021) · Microvascular Research · doi:10.1016/j.mvr.2021.104219 · Cited by 10
Quantitative analysis of the capillary network of aged APPswe/PS1dE9 transgenic mice
Nikolajsen, G. N., Kotynski, K. A., Jensen, M. S., & West, M. J. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.08.004 · Cited by 9
Therapeutic Approaches for the Treatment of Alzheimer's Disease: An Overview
Lau, L., & Brodney, M. A. (2007) · Springer eBooks · doi:10.1007/7355_2007_017 · Cited by 15
Akbari, S., Akrami, H., Mostafaei, A., & Kiani, S. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28391 · Cited by 9
“Several clinically therapeutic strategies could reduce the amyloid load in the brain such as reducing the production of Aβ or preventing oligomerization and deposition of Aβ, and enhancing Aβ degradation.(22) Most of these strategies were expensive and difficult to do, so we decided to investigate the effect of BBI on…”
BackgroundFat and Lipid Metabolism and the Involvement of Apolipoprotein E in Alzheimer's Disease
Hone, E., Lim, F., & Martins, I. J. (2019) · Wiley eBooks · doi:10.1002/9781119356752.ch7 · Cited by 9
Wei, S., Shang, S., Dang, L., Gao, F., Gao, Y., Gao, L., Chen, C., Huo, K., Wang, J., Wang, J., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210405 · Cited by 8
“A (cid:2) can be cleared from the central nervous system (CNS) to the blood via transporters through the blood-brain barrier (BBB), while reverse transport of peripheral A (cid:2) across the BBB into the brain can occur as well [4, 5].”
Serum-derived immunoglobulins alter amyloid β transport across a blood-brain barrier in vitro model
Poetsch, V., Bennani‐Baïti, B., Neuhaus, W., Muchitsch, E. M., & Noe, C. R. (2010) · Die Pharmazie · doi:10.31083/ph.2010.9319 · Cited by 8
Broeckhoven, C. V., & Kumar‐Singh, S. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2006-9s344 · Cited by 11
“A β is normally cleared through vessels by either periarterial ISF drainage pathway or by an active transport across the blood brain barrier [14,15, 61,74,101].”
Tripathi, P., & Shah, J. (2026) · Molecular Neurobiology · doi:10.1007/s12035-025-05652-4 · Cited by 7
“The clearance pathway is regulated by efflux transporters, amyloid-degrading enzymes such as neprilysin (NEP) and insulin-degrading enzyme (IDE), and microglia-mediated degradation of Aβ [6, 7].”
Wang, Z., Zhong, R., Curran, G. L., Min, H.-K. P., Lowe, V. J., Li, L., & Kandimalla, K. K. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00633 · Cited by 8
Martins, I. J., Gupta, V. B., Wilson, A. C., Fuller, S. J., & Martins, R. N. (2014) · Current Proteomics · doi:10.2174/157016461103140922163729 · Cited by 11
Zhao, Z., Hood, R. J., Ong, L. K., Pietrogrande, G., Sanchez‐Bezanilla, S., Warren, K. E., Ilicic, M., Kluge, M. G., TeBay, C., Ottersen, O. P., et al. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.585189 · Cited by 8
LRP1 in GABAergic neurons is a key link between obesity and memory function
Rodrigues, K. C. D. C., Kim, S. C., Uner, A. A., Hou, Z.-S., Young, J., Campolim, C. M., Aydogan, A., Chung, B., Choi, A., Yang, W., et al. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.101941 · Cited by 7
“The effect of LRP1 de fi ciency on A b level Since LRP1 plays an important role in A b clearance [19], we measured A b levels in the serum, brain, and liver to understand the impact of GABAergic neuron-speci fi c LRP1 de fi ciency on A b production.”
Taming Alzheimer's disease: New perspectives, newer horizons.
Sen, D., Majumder, A., Arora, V., Yadu, N., & Chakrabarti, R. (2017) · PubMed Central · Cited by 10
Cerebral Microcirculation: An Introduction
Dalkara, T. (2015) · Springer eBooks · doi:10.1007/978-3-642-37078-6_29 · Cited by 9
The influence of tumour necrosis factor- α (TNF-α) on amyloid-β (Aβ)-degrading enzymes in vitro.
Culpan, D., Palmer, J. C., Miners, J. S., Love, S., & Kehoe, P. G. (2011) · Explore Bristol Research · Cited by 9
Ji, B., Cen, J., Liu, L., & He, L. (2013) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2013.10.005 · Cited by 7
“A is secreted from neurons into brain interstitial fluid and then transported across the BBB (DeMattos et al., 2002; Shibata et al., 2000).”
BackgroundInfluentialKranenburg, O., Bouma, B., Gent, Y. Y. J., Aarsman, C. J. M., Kayed, R., Posthuma, G., Schiks, B., Voest, E. E., & Gebbink, M. F. B. G. (2004) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2004.11.001 · Cited by 8
A Vascular Connection to Alzheimer's Disease
Rhodin, J. A. G., & Thomas, T. (2001) · Microcirculation · doi:10.1111/j.1549-8719.2001.tb00170.x · Cited by 7
The role of Aβ in Alzheimer's Disease as an Evolutionary Outcome of Optimized Innate Immune Defense
Tatar, M. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2022.68 · Cited by 6
“Aβ is cleared across the blood brain barrier by chaperone-mediated transport (90, 91), while cerebrospinal fluid may enter the parenchyma to flush Aβ from the CNS (92).”
BackgroundYang, M., Ho, T., Chang, C.-C., Su, Y.-S., Yuan, C., Chuang, K., & Tyan, Y. (2023) · Molecules · doi:10.3390/molecules28165938 · Cited by 8
“LRP1B also plays a role in removing β-amyloid across the blood–brain barrier [26], and its reduced or absent expression may result in decreased clearance of β-amyloid and ApoE/α2-macroglobulin complexes, thereby increasing the risk of Alzheimer’s disease.”
BackgroundPatil, S. P., & Kuehn, B. R. (2024) · Pharmaceuticals · doi:10.3390/ph17040491 · Cited by 8
“The different ApoE isoforms may also compete differentially with soluble A β for uptake by astrocytes through the low-density lipoprotein receptor-related protein 1 (LRP1) mechanism [29], which is also involved in peripheral clearance of A β across the blood–brain barrier [30].”
BackgroundModulating Role of TTR in Aβ Toxicity, from Health to Disease
Cardoso, I., Santos, L. M., & Alemi, M. (2016) · InTech eBooks · doi:10.5772/63194 · Cited by 8
“For instance: decreased LRP1 expression in human brain microvasculature [239], increased LRP1 oxidative damage [259], impaired microvascular P-gp [260], increased expression of RAGE in the cerebral vessels, neurons and microglia [251].”
InfluentialHou, H., Habib, A., Zi, D., Tian, K., Tian, J., Giunta, B. N., Sawmiller, D. R., & Tan, J. (2017) · NeuroMolecular Medicine · doi:10.1007/s12017-017-8446-x · Cited by 6
Duong, Q.-V., Kintzing, M. L., Kintzing, W. E., Abdallah, I. M., Brannen, A. D., & Kaddoumi, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061489 · Cited by 7
“In brief, at the end of the treatment, animals were intraperitoneally anesthetized with xylazine and ketamine (20 and 125 mg/kg, respectively), followed by the insertion of a stainless-steel guide cannula into the right caudate nucleus, an area rich with blood microvessels, of the mice’s brain following previously est…”
MethodDesign and characterization of a novel dimeric blood–brain barrier penetrating TNFα inhibitor
Suárez, V. M., Macaya, L., Contreras, M. A., Parra, N. C., Maura, R., González, A., Toledo, J. R., & Sánchez, O. (2021) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26173 · Cited by 6
Dudchenko, N. G., Chimagomedova, A. S., Васенина, Е. Е., & Levin, O. S. (2022) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202212207120 · Cited by 6
Rai, A., Ojiakor, O. A., & Rylett, R. J. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15904 · Cited by 7
CD36 expression in the brains of SAMP8
Wu, B., Ueno, M., Kusaka, T., Miki, T., Nagai, Y., Nakagawa, T., Kanenishi, K., Hosomi, N., & Sakamoto, H. (2012) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2012.07.007 · Cited by 6
Multifunctional Effects of Human Serum Albumin Toward Neuroprotection in Alzheimer Disease
Ezra, A., Rabinovich-Nikitin, I., Rabinovich‐Toidman, P., & Solomon, B. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803690-7.00011-9 · Cited by 8
Blood–Brain Barrier Transporters and Neuroinflammation: Partners in Neuroprotection and in Pathology
Makrides, V., Dolgodilina, E., & Virgintino, D. (2017) · Springer eBooks · doi:10.1007/978-3-319-45514-3_6 · Cited by 6
Wei, S., Gao, L., Jiang, Y., Shang, S., Chen, C., Dang, L., Zhao, B., Zhang, J., Wang, J., Huo, K., et al. (2019) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.06.011 · Cited by 6
van der Willik, K. D., Ghanbari, M., Fani, L., Compter, A., Ruiter, R., Stricker, B. H. C., Schagen, S. B., & Ikram, M. A. (2020) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-20-0167 · Cited by 7
“Although endothelial cells of blood vessels and platelets are the main source of circulating Ab (14), Ab is also produced by neuronal cells and is subsequently transported across the blood– brain barrier (15).”
BackgroundPolymers for the treatment of Alzheimer’s disease
Zhu, Y., Xu, H., Yu, C., Jiang, W., Hou, X., Ma, M., & Wu, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1512941 · Cited by 5
Liu, Y., Initiative, A. D. N., Wang, X.-J., Tan, L., Tan, C., & Xu, W. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230516 · Cited by 6
A Novel Perspective on PCSK9 in Alzheimer’s Disease: A Focus on Amyloid Beta
Zhang, H., Xu, Q. F., Zhao, Y., He, N., Ren, Z., Xiang, Q., Tang, Z., & Liu, L. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673269288231123095215 · Cited by 8
Zhang, D., Wang, Z., Wang, X., Yue, W., Zhang, L., Gao, Z., Li, M., Zhou, X., Li, Z., Huang, G., et al. (2025) · Lipids · doi:10.1002/lipd.12436 · Cited by 5
“Low-density lipoprotein receptor-related peptide 1 (LRP1) and low-density lipoprotein receptor (LDLR)-mediated brain A β transport across the BBB into the periphery is a vital potential pathway for A β clearance (Castellano et al., 2012; Shibata et al., 2000).”
Bohannon, D. G., Long, D., Okhravi, H. R., Lee, S. C., Jesus, C. L. D., Neubert, T. A., Rostagno, A. A., Ghiso, J. A., & Kim, W. (2024) · Brain Pathology · doi:10.1111/bpa.13282 · Cited by 5
Self-citationAhmad, S. S., & Kamal, M. A. (2019) · Protein and Peptide Letters · doi:10.2174/0929866526666190405125334 · Cited by 6
Terasaki, T., & Ohtsuki, S. (2005) · Neurotherapeutics · doi:10.1007/bf03206643 · Cited by 9
Effects of taurine on metal cations, transthyretin and LRP-1 in a rat model of Alzheimer’s disease
Tekin, E., Karakelle, N. A., & Dinçer, S. (2023) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2023.127219 · Cited by 6
Antiaging methods and medicines for the memory
Banks, W. A., & Farr, S. A. (2004) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2004.02.007 · Cited by 5
Role of apoE in conformation-prone diseases and atherosclerosis
Dergunov, A. D. (2006) · Biochemistry (Moscow) · doi:10.1134/s0006297906070029 · Cited by 6
Lipids and Lipoproteins in Alzheimer’s Disease
Stukas, S. K., Kulić, I., Zareyan, S., & Wellington, C. L. (2015) · InTech eBooks · doi:10.5772/59808 · Cited by 6
“LRP1 can bind Aβ directly or bind apoE-associated Aβ to internalize and transport soluble Aβ across the BBB to plasma for eventual degradation, or mediate degradation within cell lysosomes [262-266].”
BackgroundErickson, M. A., Nicolazzo, J. A., & Banks, W. A. (2018) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2018.08.016 · Cited by 5
Amyloid Hypothesis and Alzheimer's Disease
Sun, X., & Zhang, Y. (2011) · InTech eBooks · doi:10.5772/28947 · Cited by 4
Marsland, P., Vore, A. S., Lutzke, A., Gano, A., Fischer, A., Trapp, S., Savage, L. M., & Deak, T. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.03.034 · Cited by 4
Mee-inta, O., Chiang, Y.-Y., Tsai, S., Yang, T., Zhao, Z., Wang, T.-F., Wu, H.-Y., Hsiung, C.-W., Liao, P.-C., Lee, H., et al. (2026) · Acta Neuropathologica Communications · doi:10.1186/s40478-025-02218-2 · Cited by 4
“However, more recent studies suggest that the glym-phatic system may also be a crucial elimination pathway, transporting A β from the brain interstitial fluid into the cerebrospinal fluid (CSF) [4, 5, 7].”
InfluentialHartmann, C., Haferkamp, U., Appelt‐Menzel, A., Barenberg, J., Brachner, A., Ehrhard, T., Feldhaus, J. S., Gerhartl, A., Hollemann, T., Kulka, L. A. M., et al. (2026) · Fluids and Barriers of the CNS · doi:10.1186/s12987-025-00753-7 · Cited by 4
Transport pathways across the blood-brain barrier for waste clearance and drug delivery
Gröbner, L. S., & Pietrzik, C. U. (2026) · Fluids and Barriers of the CNS · doi:10.1186/s12987-026-00812-7 · Cited by 4
“Some proteins such as Aβ, insulin, or transferrin have specific receptors at the BBB, managing the systemic clearance [159–161].”
Huang, S., Nunez, J., Toresco, D. L., Wen, C., Slotabec, L. A., Wang, H., Zhang, H., Rouhi, N., Adenawoola, M. I., & Li, J. (2025) · The FASEB Journal · doi:10.1096/fj.202402725rr · Cited by 8
“128 In the 5xFAD mouse AD model, specific deletion of Lrp1 in brain endothelial cells resulted in reduced plasma A β levels and increased soluble brain A β , which exacerbated deficits of spatial learning and memory.”
Innate Immune Mechanisms in the Central Nervous System
Shastri, A., Yasmin, H., & Kishore, U. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-85340-1_15 · Cited by 4
Salian, V. S., Curran, G. L., Lowe, V. J., Tang, X., Kalari, K. R., & Kandimalla, K. K. (2025) · Molecular Pharmacology · doi:10.1016/j.molpha.2025.100088 · Cited by 6
Shared whole environmental etiology between Alzheimer’s disease and age-related macular degeneration
Ye, S., Ma, S., Liu, S., Huang, Y., Li, D., Li, M., Su, T., Luo, J., Zhang, C., Shi, D., et al. (2024) · npj Aging · doi:10.1038/s41514-024-00162-4 · Cited by 5
“Enhancing the expression of this receptor could be a promising therapeutic strategy for AD 56,57 .”
BackgroundThe role of APP in Alzheimer’s disease
Pung, L., Wang, X., Li, M., & Xue, L. (2013) · Advances in Alzheimer s Disease · doi:10.4236/aad.2013.22008 · Cited by 4
“Loss of function of low density lipoprotein receptorrelated protein (LRP) has been implicated in decreased Aβ clearance in mice and has been genetically linked in epidemiological studies to AD pathogenesis [51, 52].”
Zhang, C., Yang, T., Wang, J., Liu, G., & Chen, Q. (2005) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2004.12.023 · Cited by 4
Extracellular Amyloid-β Protein Dynamics in Alzheimer’s Disease
Cirrito, J. R. (2012) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-1-4614-4815-0_9 · Cited by 4
Dudal, S., Morissette, C., Lacombe, D., Tremblay, P., & Gervais, F. (2004) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2004.04.014 · Cited by 7
Neuronal aging potentiates beta-amyloid generation via amyloid precursor protein endocytosisPreprint
Burrinha, T., Gomes, R. A., Terrasso, A. P., & Almeida, C. G. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/616540 · Cited by 6
Corraliza-Gómez, M. (2021) · UVaDOC UVaDOC University of Valladolid Documentary Repository (University of Valladolid) · doi:10.35376/10324/51889 · Cited by 6
Regulation of the Blood–Brain Barrier in Health and Disease
Rada, C. C., Yuki, K., Ding, J., & Kuo, C. J. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041191 · Cited by 4
Chintamaneni, P. K., Pindiprolu, S. K. S. S., Krishnamurthy, P. T., & Varshini, M. S. (2024) · Springer eBooks · doi:10.1007/978-981-96-0259-9_12 · Cited by 3
Metabolic profiles of the human blood-brain barrier cells treated by TNF-alpha and oxysterols
Nguyen, C. M., Cheung, K. C.-P., Chen, X., Saint‐Pol, J., Shimizu, F., Kanda, T., Pot, C., Culot, M., Chan, K. W. Y., Lu, W., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118853 · Cited by 4
Semyachkina-Glushkovskaya, O. V., Sursaev, V. A., Poluektov, M. G., Diduk, S., Rychkova, L., Михайловна, М. И., Yakubova, L., & Kurths, J. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052312 · Cited by 5
A Age Related Vascular Senescence: Mystery of Blood-brain Barrier Dysfunction in Neurodegeneration
Behl, T., Jayabalan, K., Ballal, S., Sahoo, S., Chellammal, H. S. J., Gulati, M., Anand, K., Jha, S. K., & Gasmi, A. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-05984-9 · Cited by 3
“For instance, in AD, lower levels of GLUT1 and LRP1 at the BBB are linked to both BBB breakdown and progressive neurodegeneration [72, 74].”
Hatip, F. F. B., Matsunaga, Y., & Yamada, T. (2007) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2007.00959.x · Cited by 3
“The Ab binding agents in the plasma such as anti-Ab antibody (9), gelsolin, ganglioside M1 and receptor for advanced glycation end products (10) and low-density lipoprotein receptor-related protein (11) are involved in cleaning out the Ab in the plasma.”
BackgroundBlossom, V., Ullal, S. D., Rai, R., Hegde, A., Rai, S., & Anita Sherly, A. (2026) · Oxygen · doi:10.3390/oxygen6020006 · Cited by 3
Greenberg, S. M. (2009) · Cambridge University Press eBooks · doi:10.1017/cbo9780511691836.005 · Cited by 3
Aging: Thromboembolic Disease, Metabolic Syndrome, Type 2 Diabetes Mellitus, and Alzheimer’s Disease
Lasierra-Cirujeda, J., Pascual-Salcedo, M. J. A., Lasierra-Ibañez, A., AZA, C. L., & Aza‐Pascual‐Salcedo, M. (2016) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2016.45001 · Cited by 5
Stable Isotope Labeling Kinetics in CNS Translational Medicine: Introduction to SILK Technology
Bateman, R. J., West, T., Yarasheski, K. E., Patterson, B. W., Lucey, B. P., Cirrito, J. R., Lehmann, S., Hirtz, C., Gabelle, A., Miller, T. M., et al. (2019) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-803161-2.00011-4 · Cited by 4
Alzheimer Dementia and Microvascular Pathology: Blood-Brain Barrier Permeability Imaging
Moon, W. (2020) · Journal of the Korean Society of Radiology · doi:10.3348/jksr.2020.81.3.488 · Cited by 5
“기존 연구들에서 는 Aβ의 75%를 BBB가 제거하고, 글림파틱시스템이 10%를 담당하는 것으로 보고 있으나(64), 기 존의 생각보다는 더 많은 정도의 Aβ 제거를 글림파틱시스템이 담당할지도 모른다는 주장을 뒷받 침하는 최근 동물실험 결과도 있다(62, 63).”
Mettenburg, J., Arandjelovic, S., & Gonias, S. L. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02995.x · Cited by 4
“…has been associated with increased amyloid deposition (Kang et al. 2000). a2M and endothelial cell LRP-1 transport Ab across the blood–brain barrier, away from the CNS and into the plasma (Shibata et al. 2000), which may substantially influence Ab deposition in the brain (Ghersi-Egea et al. 1996).”
BackgroundCao, Z.-K., Lv, J., & Quan, W. (2010) · International Journal of Neuroscience · doi:10.3109/00207454.2010.520379 · Cited by 3
“Aβ can be absorbed into the blood via the lowdensity-lipoprotein receptor-related protein-1 (LRP-1; Shibata et al., 2000).”
BackgroundBoada, M., Ortiz, P., Hernández, I., Muñoz, J., Núñez, L., Olazarán, J., Cuberas‐Borrós, G., & Tárraga, L. (2009) · Cited by 4
Therapeutics of Alzheimer’s Disease
Herrera-Rivero, M., & Emiliano, G. (2011) · InTech eBooks · doi:10.5772/27990 · Cited by 3
Alzheimer Disease and Metabolism: Role of Cholesterol and Membrane Fluidity
Genaro, G., Fermin, P., Luis, J., Miguel, A., Irma, E., Anguiano, A., Torres-Sánchez, E. D., Eddic, W., Jose, A., Genaro, E., et al. (2013) · InTech eBooks · doi:10.5772/54091 · Cited by 5
The role of proteotoxic stress in vascular dysfunction in the pathogenesis of Alzheimer’s disease
Fonseca, A. C. R. G., Resende, R., Cardoso, S. M., & Pereira, C. (2015) · Endoplasmic Reticulum Stress in Diseases · doi:10.1515/ersc-2015-0005 · Cited by 4
“In accordance, brain regions affected by AD have increased expression of RAGE [79] and a downregulation of LRP1 that is associated with Aβ deposition in the cerebral vessels of aged animals and AD patients [80].”
BackgroundLRP1 and Cerebral Amyloid Angiopathy
Kanekiyo, T., & Bu, G. (2008) · Future Neurology · doi:10.2217/14796708.4.1.55 · Cited by 4
Metadata
- Authors
- Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., & Zlokovic, B. V.
- Affiliations
- University of Southern California (US)
- NYU Langone Health (US)
- Washington University in St. Louis (US)
- American Red Cross (US)
- University of Rochester Medicine (US)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2000-12-15
- Volume
- 106
- Issue
- 12
- Pages
- 1489-1499
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC387254
- OpenAlex
- W1997822484
- Cited by
- 1,413
- References
- 76
- Citations by year
- 2026: 38 · 2025: 60 · 2024: 58 · 2023: 59 · 2022: 57 · 2021: 75 · 2020: 85 · 2019: 73 · 2018: 52 · 2017: 67 · 2016: 64 · 2015: 56 · 2014: 60 · 2013: 62 · 2012: 60
- FWCI
- 15.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p01ag016223-04)
- National Institute on Aging (R37AG005891, R01AG013956, P50AG005142, AG16223, R37AG013956, AG05891)
- National Heart, Lung, and Blood Institute (R01HL050784)
- National Institute of Neurological Disorders and Stroke (NS 33466, R01NS038777)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- Aβ40, Alzheimer's disease, blood-brain barrier, LDL receptor-related protein 1, receptor-associated protein, alpha2-macroglobulin, apolipoprotein E, amyloid-beta clearance, efflux transport, cerebral microvasculature, amyloid-beta deposition
- MeSH terms
- Aging, alpha-Macroglobulins, Alzheimer Disease, Amino Acid Sequence, Animals, Apolipoproteins E, Biological Transport, Blood-Brain Barrier, Brain, Catheterization, Genotype, Half-Life, Humans, Immunohistochemistry, Inulin, Iodine Radioisotopes, Kinetics, Male, Mice, Inbred C57BL, Molecular Sequence Data, Peptide Fragments, Receptors, Immunologic, Amyloid beta-Peptides, Mice, Knockout, Low Density Lipoprotein Receptor-Related Protein-1, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-11-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.






